Oxbryta - direct healthcare professional communication (DHPC)

Voxelotor
DHPCHuman

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Oxbryta
Active substance
Voxelotor
Therapeutic area (MeSH)
  • Anemia
  • Anemia, Hemolytic
  • Anemia, Sickle Cell
Procedure number
EMEA/H/A-20/1538/C/004869/0014
Regulatory outcome
Suspension
DHPC type
Referral - Article 20 procedure
Human ATC codes
B06AX03
Dissemination date
Oxbryta

Share this page